Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473)

Anti-Cancer Drug Design

Volumn 13, Issue 1, 1998, Pages 1-18

  Holford, Jeffrey ^a   Raynaud, Florence ^a   Murrer, Barry A ^b   Grimaldi, Keith ^c   Hartley, John A ^c   Abrams, Michael ^d   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Anor MED Inc   (Canada)

Author keywords

AMD473; Circumvention; Platinum; Resistance

Indexed keywords

AMD 494; AMD 508; CARBOPLATIN; CELL DNA; CIS AMMINEDICHLORO(2 METHYLPYRIDINE) PLATINUM(II); CISPLATIN; PLASMID DNA; PLATINUM COMPLEX; SATRAPLATIN; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA ADDUCT; DNA CROSS LINKING; DNA SEQUENCE; DRUG ACTIVITY; DRUG DNA BINDING; DRUG HYDROLYSIS; DRUG RESISTANCE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; STEREOSPECIFICITY;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DNA; DNA ADDUCTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOTION; ORGANOPLATINUM COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; WATER;

EID: 0031962943     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. BARNHAM, K.J., DJURAN, M.I., MURDOCH, P. DEL S. & SADLER, RI (1994a). Intermolecular displacement of S-bound L-methionine on platinum(II) by guanosine 5′-monophosphate: implications for the mechanism of action of anticancer drugs. JCS Chemical Communications, 721.
2. 2(L-methionine-S)]: ring-opened adduct of the anticancer drug carboplatin ('Paraplatin'). Detection of a similar complex in urine by NMR spectroscopy. Journal of the American Chemistry Society, 116, 11175.
3. BEHRENS, B.C., HAMILTON, T.C., MASUDA, H., GROTZINGER, K.R., WHANG-PENG, J., LOUIE, K.G., KNUTSEN, T., MCKOY, W.M., YOUNG, R.C. & OZOLS, R.F. (1987).Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cell line and its use in evaluation of platinum analogs. Cancer Research, 47, 414.
4. FICHTINGER-SCHEPMAN, A.M.J., VAN DER VEER, J.L., DEN HARTOG, J.H.J., LOHMAN, P.H.M. & REEDUK, J. (1985). Adducts of the antitumour drug cis-diamminedichloro platinum(II) with DNA: formation, identification and quantitation. Biochemistry, 24, 707.
5. GORE, M., FRYATT, I., WILTSHAW, E., DAWSON, T., ROBINSON, B. & CALVERT, A. (1989). Cisplatin/carboplatin cross-resistance in ovarian cancer. British Journal of Cancer, 60, 767.
6. GRIMALDI, K.A., MCADAM, S.R., SOUHAMI, R.L. & HARTLEY, J.A. (1994). DNA damage by anti-cancer agents resolved at the nucleotide level of a single copy gene: evidence for a novel binding site for cisplatin in cells. Nucleic Acids Research, 22, 2311.
7. HARRAP, K.R. (1985). Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treatment Reviews, 12(suppl. A), 21.
8. HARTLEY, J.A., BERARDINI, M.D. & SOUHAMI, R.L. (1991). An agarose gel method for the determination of DNA interstrand crosslinking applicable to the measurement of the rate of total and 'second-arm' crosslink reactions. Analytical Biochemistry, 193, 131.
9. HOLFORD, J., SHARP, S.Y., MURRER, B.A. & KELLAND, L.R. (1996). In vitro evaluation of JM473, a novel sterically hindered platinum(II) complex. Analytical Oncology, 7(suppl. 1), 37, abstract 122.
10. JOHNSON, S.W., PEREZ. R.P., GODWIN, A.K., YEUNG, A.T., HANDEL, L.M., OZOLS, R.F. & HAMILTON, T.C (1994). Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochemistry Pharmacology, 47, 689.
11. KELLAND, L.R. (1993). New platinum antitumour complexes. Critical Reviews in Oncologyl Hematology, 15, 191.
12. KELLAND, L.R., JONES, M., ABEL, G., VALENTI, M., GWYNNE, J. & HARRAP, K.R. (1992a). Human ovarian-carcinoma cell lines and companion xenografts: a disease-orientated approach to new platinum anticancer drug discovery. Cancer Chemotherapy and Pharmacology, 30, 43.
13. KELLAND, L.R., MURRER, B.A., ABEL, G., GIANDOMENICO, C.M., MISTRY, P. & HARRAP, K.R. (1992b). Ammine/ amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian cell lines. Cancer Research, 52, 822.
14. KELLAND, L.R., BARNARD, C.F.J., MELLISH, K.J., JONES, M., GODDARD, P.M., VALENTI, M., BRYANT, A., MURRER, B.A. & HARRAP, K.R. (1994). A novel trans-platinum coordination complex possessing in vitro and in vivo antitumour activity. Cancer Research, 54, 5618.
15. KOHN, K.W. (1987). DNA filter elution methods in anticancer drug development. Cancer Treatment Research, 36, 3.
16. LAI, G.M., OZOLS, R.F., YOUNG, R.C. & HAMILTON, T.C. (1989). Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. Journal of the National Cancer Institute, 81, 535.
17. LOEHRER, P.J. & EINHORN, L.H. (1984). Cisplatin, diagnosis and treatment. Annals of Internal Medicine, 100, 704.
18. LOH, S.Y., MISTRY, P., KELLAND, L.R., ABEL, G & HARRAP, K.R. (1992). Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. British Journal of Cancer, 66, 1109.
19. MISTRY P., KELLAND, L.R., ABEL, G., SIDHR, S. & HARRAP, K.R. (1991). The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. British Journal of Cancer, 64, 215.
20. NISHIMURA, T., NEWKIRK, K., SESSIONS, R.B., ANDREWS, P.A., TROCK, B.J., RASMUSSEN, A.A., MONTGOMERY, E.A., BISCHOFF, E.K. & CULLEN, K.J. (1996). Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clinical Cancer Research, 2, 1859.
21. O'NEILL, C.F., ORR, R.M., KELLAND, L.R. & HARRAP, K.R. (1995). Comparison of platinum (Pt) binding to DNA, and removal of total Pt adducts and interstrand crosslinks in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Cell Pharmacology, 2, 1.
22. PENDYALA, L., CREAVEN, P.J., PEREZ, R., ZDANOICZ, J.R. & RAGHAVAN, D. (1995). Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemotherapy Pharmacology, 36, 271.
23. PONTI, M., FORROW, S.M., SOUHAMI, R.L., D'INCALCI, M. & HARTLEY, J.A. (1991). Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Research, 19, 2929.
24. RILEY, C.M., STERNSON, L.A., REPTA, A.J. & SLYTER, S.A. (1983). Monitoring the reactions of cisplatin with nucleotides and methionine by reversed-phase high-performance liquid chromatography using cationic and anionic pairing ions. Analytical Biochemistry, 130, 203.
25. SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS, A., MCMAHON, J., VISITICA, D., WARREN, J., BOKESCH, H., KENNEDY, S. & B́OYD, M.R. (1990). New colorimetric cytotoxicity assay for anticancer drug screening. Journal of the National Cancer Institute, 82, 1107.
26. SMELLIE, M., KELLAND, L.R., THURSTON, D.E., SOUHAMI, R.L. & HARTLEY, J.A (1994). Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents. British Journal of Cancer, 70, 48.
27. VERSANTVOORT, C.H.M., BROXTERMAN, H.J., BAGRIJ, T., SCHEPER, R.J. & TWENTYMAN, P.R. (1995). Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. British Journal of Cancer, 72, 82.
28. YARBO, J.W. (ed.) (1992). Carboplatin (JM8) update: current perspectives and future directions. Seminars in Oncology, 19(suppl. 2), 1.